학술논문
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Document Type
journal article
Author
Source
Expert Review of Anticancer Therapy; Dec2015, Vol. 15 Issue 12, p1389-1403, 15p
Subject
Language
ISSN
14737140
Abstract
Copyright of Expert Review of Anticancer Therapy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)